Cover Image

The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetesResearch in context

Summary: Background: A delay in reaching HbA1c targets in patients with newly-diagnosed type 2 diabetes (T2D) is associated with an increased long-term risk of developing cardiovascular diseases (CVD), a phenomenon referred to as legacy effect. Whether an early introduction of glucose-lowering drugs...

Full description

Saved in:

Bibliographic Details
Main Authors:	Antonio Ceriello (Author), Giuseppe Lucisano (Author), Francesco Prattichizzo (Author), Rosalba La Grotta (Author), Chiara Frigé (Author), Salvatore De Cosmo (Author), Paolo Di Bartolo (Author), Graziano Di Cianni (Author), Paola Fioretto (Author), Carlo Bruno Giorda (Author), Roberto Pontremoli (Author), Giuseppina Russo (Author), Francesca Viazzi (Author), Antonio Nicolucci (Author)
Format:	Book
Published:	Elsevier, 2023-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesResearch in context
by: Luis A. Rodriguez, et al.
Published: (2024)

Acido urico, spettatore o artefice dell'aumentato rischio cardiovascolare e renale?
by: Francesca Viazzi, et al.
Published: (2013)

Cardiovascular and renal effects of hyperuricaemia and gout
by: R. Pontremoli, et al.
Published: (2012)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

Corrigendum to "Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?"
by: Angelica Giuliani, et al.
Published: (2019)

Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?
by: Angelica Giuliani, et al.
Published: (2017)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023)

Use systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
by: Yasong eLu, et al.
Published: (2014)

The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022)

SGLT2 Inhibitors and Fracture Risk in Elderly Population
by: Vishal R Tandon, et al.
Published: (2023)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
by: Saverio Muscoli, et al.
Published: (2022)

GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress
by: Ceriello A, et al.
Published: (2015)

CONTINUED OPTIMIZATION OF USE OF SGLT-2I FOR HF: IMPROVING PRESCRIPTION REFILLS OF SGLT2I AT UT TYLER INTERNAL MEDICINE RESIDENT CLINIC
by: Mariam Qazi, DO
Published: (2024)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
by: Nauck MA
Published: (2014)

SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
by: Mariana Silva de Sousa, et al.
Published: (2023)

SGLT2-Inhibitors - significant role in Heart Failure treatment
by: Karol Wielgus, et al.
Published: (2024)

Emerging data on SGLT2 benefits in acute coronary syndromes
by: Aidin Rawshani
Published: (2024)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
by: Pasquale Paolisso, et al.
Published: (2023)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
by: Maria Elena Lunati, et al.
Published: (2022)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024)

Psoriasiform lesions as a side effect of SGLT-2 therapy
by: Jakub Krzysztof Gałązka, et al.
Published: (2023)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
by: Lea El Hage MD, et al.
Published: (2019)

SGLT-2 inhibitors: new effective drugs for treatment of heart failure
by: Olgierd Król, et al.
Published: (2022)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022)

Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
by: Min Sun, et al.
Published: (2024)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model
by: Oleg eDemin Jr, et al.
Published: (2014)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
by: Aurélie Pahud de Mortanges, et al.
Published: (2021)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023)

Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports
by: Joanna Winciorek, et al.
Published: (2024)